Ncardia innovative hiPSC-based products and services for drug discovery & development

We’re shaping the future of drug discovery & development

Ncardia is a stem cell drug discovery & development company operating worldwide with facilities and offices in Belgium, the Netherlands, and the USA. Ncardia is built on the belief and trust that stem technology will help to get better medicines to patients faster. The goal of the company is to be the supportive and trusted partner for scientists operating in the hiPSC drug discovery and development space including cardiovascular and neural safety and efficacy studies.

The cardiac products encompass hiPSC-derived cardiomyocytes and a broad neural cell portfolio includes CNS.4U®, Peri.4U® peripheral neurons and Astro.4U® astrocytes. In addition, Ncardia develops and provides its customers with a broad portfolio of cardiovascular services from disease modeling to cardiovascular drug efficacy screening along with cardiac safety assessment.

Our history

Ncardia originates from the biotech company Pluriomics that was founded in 2011 by Stefan Braam and Herman Spolders, together with the scientific founders Prof. Dr. Mummery and Prof. Dr. Passier.

Their first product was the Pluricyte Cardiomyocyte Kit that was introduced to the cardiac safety market in 2014. At the moment Ncardia is a leading provider in human cardiovascular and neural stem cell technology, disease modeling and cell-based assay products and services for drug discovery. Their people, products, services, industry knowledge and expertise to develop and generate more innovative stem cell based products and services brought Ncardia to this level.

Board of Directors

The Board of Directors of Ncardia consists of:

  • Alain Parthoens (Chairman of the Board, AQ Invest BVBA)
  • Stefan Braam (CEO, Ncardia)
  • Jean Paul Prieels (SFPI-FPIM)
  • Philippe Degive (Sparaxis SA)
  • Alex Liu Hua (Sino-German beta Holding Co. Ltd)
  • Michael Vogel
  • Guy Heynen


Ncardia is a privately held Belgium-based company with subsidiaries in the Netherlands and the USA. The investor base of the company includes both public and private funds including Vesalius Biocapital, SFPI-FPIM, SambrInvest, InnovationQuarter, S.R.I.W, Sino-German beta Holding Co. Ltd and founders.

Management team

Ncardia has attracted a leadership team of international experts in the areas of commercialization, pharma services, finance, stem cell R&D and manufacturing.

The management team consists of: